COVID-19 Funds Flow To Startup In Bid To Restore US Pharmaceutical Manufacturing

20 May 2020

Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.

PS2005_Pharma Factory_266841464_1200 — domestic us pharma manufacturing startup funded • Source: Shutterstock

The federal response to the coronavirus pandemic has put a Richmond, VA, start-up called Phlow Corp. in the role of preventing shortages of essential medicines and shielding the US market from global competition, particularly from China.

The decision the Health and Human Services Department announced 19 May to provide Phlow with $354m of COVID-19 response funding...